BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yang X, Qian Y, Xu S, Song Y, Xiao Q. Longitudinal Analysis of Fecal Microbiome and Pathologic Processes in a Rotenone Induced Mice Model of Parkinson's Disease. Front Aging Neurosci 2017;9:441. [PMID: 29358918 DOI: 10.3389/fnagi.2017.00441] [Cited by in Crossref: 50] [Cited by in F6Publishing: 69] [Article Influence: 12.5] [Reference Citation Analysis]
Number Citing Articles
1 Wang X, Jiang D, Li T, Zhang X, Wang R, Gao S, Yang F, Wang Y, Tian Q, Xie C, Liang J. Association between microbiological risk factors and neurodegenerative disorders: An umbrella review of systematic reviews and meta-analyses. Front Psychiatry 2022;13:991085. [DOI: 10.3389/fpsyt.2022.991085] [Reference Citation Analysis]
2 Yan Z, Li R, Shi W, Yao L. Role of the gut-microbiota-metabolite axis in the rotenone model of early-stage Parkinson's Disease. Metab Brain Dis 2022. [PMID: 35895243 DOI: 10.1007/s11011-022-01004-6] [Reference Citation Analysis]
3 Tan AH, Lim SY, Lang AE. The microbiome-gut-brain axis in Parkinson disease - from basic research to the clinic. Nat Rev Neurol 2022. [PMID: 35750883 DOI: 10.1038/s41582-022-00681-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
4 Shandilya S, Kumar S, Kumar Jha N, Kumar Kesari K, Ruokolainen J. Interplay of gut microbiota and oxidative stress: Perspective on neurodegeneration and neuroprotection. Journal of Advanced Research 2022;38:223-44. [DOI: 10.1016/j.jare.2021.09.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
5 Olubodun-Obadun TG, Ishola IO, Adeyemi OO. Impact of environmental toxicants exposure on gut-brain axis in Parkinson disease. Drug Metab Pers Ther 2022. [PMID: 35377569 DOI: 10.1515/dmpt-2021-0144] [Reference Citation Analysis]
6 Cheng X, Ai K, Yi L, Liu W, Li Y, Wang Y, Zhang D. The mmu_circRNA_37492/hsa_circ_0012138 function as potential ceRNA to attenuate obstructive renal fibrosis. Cell Death Dis 2022;13:207. [PMID: 35246505 DOI: 10.1038/s41419-022-04612-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
7 Wang Q, Wang Y, Liu Z, Guo J, Li J, Zhao Y. Improvement effect of acupuncture on locomotor function in Parkinson disease via regulating gut microbiota and inhibiting inflammatory factor release. J Acupunct Tuina Sci . [DOI: 10.1007/s11726-022-1297-5] [Reference Citation Analysis]
8 Kim HS, Son J, Lee D, Tsai J, Wang D, Chocron ES, Jeong S, Kittrell P, Murchison CF, Kennedy RE, Tobon A, Jackson CE, Pickering AM. Gut- and oral-dysbiosis differentially impact spinal- and bulbar-onset ALS, predicting ALS severity and potentially determining the location of disease onset. BMC Neurol 2022;22:62. [PMID: 35189854 DOI: 10.1186/s12883-022-02586-5] [Reference Citation Analysis]
9 Alfonsetti M, Castelli V, d'Angelo M. Are We What We Eat? Impact of Diet on the Gut-Brain Axis in Parkinson's Disease. Nutrients 2022;14:380. [PMID: 35057561 DOI: 10.3390/nu14020380] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
10 Yan Z, Yang F, Wen S, Ding W, Si Y, Li R, Wang K, Yao L. Longitudinal metabolomics profiling of serum amino acids in rotenone-induced Parkinson's mouse model. Amino Acids 2022. [PMID: 35028704 DOI: 10.1007/s00726-021-03117-1] [Reference Citation Analysis]
11 Pellegrini C, D'Antongiovanni V, Miraglia F, Rota L, Benvenuti L, Di Salvo C, Testa G, Capsoni S, Carta G, Antonioli L, Cattaneo A, Blandizzi C, Colla E, Fornai M. Enteric α-synuclein impairs intestinal epithelial barrier through caspase-1-inflammasome signaling in Parkinson's disease before brain pathology. NPJ Parkinsons Dis 2022;8:9. [PMID: 35022395 DOI: 10.1038/s41531-021-00263-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
12 Liu J, Zhang Y, Ye T, Yu Q, Yu J, Yuan S, Gao X, Wan X, Zhang R, Han W, Zhang Y. Effect of Coffee against MPTP-Induced Motor Deficits and Neurodegeneration in Mice Via Regulating Gut Microbiota. J Agric Food Chem 2022;70:184-95. [PMID: 35016506 DOI: 10.1021/acs.jafc.1c06998] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
13 Mancinelli AM, Vichich JM, Zinnen AD, Hugon AM, Bondarenko V, Metzger JM, Simmons HA, Golos TG, Emborg ME. Acute Exposure to the Food-Borne Pathogen Listeria monocytogenes Does Not Induce α-Synuclein Pathology in the Colonic ENS of Nonhuman Primates. J Inflamm Res 2021;14:7265-79. [PMID: 34992416 DOI: 10.2147/JIR.S337549] [Reference Citation Analysis]
14 Xu S, Yang X, Qian Y, Luo Q, Song Y, Xiao Q. Analysis of serum levels of organochlorine pesticides and related factors in Parkinson's disease. Neurotoxicology 2021;88:216-23. [PMID: 34864106 DOI: 10.1016/j.neuro.2021.12.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Khedr EM, Ali AM, Deaf E, Hassan HM, Alaa A, Gamea A. Gut microbiota in Parkinson’s disease patients: hospital-based study. Egypt J Neurol Psychiatry Neurosurg 2021;57. [DOI: 10.1186/s41983-021-00407-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Sharma M, Kaur J, Rakshe S, Sharma N, Khunt D, Khairnar A. Intranasal Exposure to Low-Dose Rotenone Induced Alpha-Synuclein Accumulation and Parkinson's Like Symptoms Without Loss of Dopaminergic Neurons. Neurotox Res 2021. [PMID: 34817799 DOI: 10.1007/s12640-021-00436-9] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
17 Yu D, Meng X, de Vos WM, Wu H, Fang X, Maiti AK. Implications of Gut Microbiota in Complex Human Diseases. Int J Mol Sci 2021;22:12661. [PMID: 34884466 DOI: 10.3390/ijms222312661] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Zhao Z, Ning J, Bao XQ, Shang M, Ma J, Li G, Zhang D. Fecal microbiota transplantation protects rotenone-induced Parkinson's disease mice via suppressing inflammation mediated by the lipopolysaccharide-TLR4 signaling pathway through the microbiota-gut-brain axis. Microbiome 2021;9:226. [PMID: 34784980 DOI: 10.1186/s40168-021-01107-9] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
19 Deidda G, Biazzo M. Gut and Brain: Investigating Physiological and Pathological Interactions Between Microbiota and Brain to Gain New Therapeutic Avenues for Brain Diseases. Front Neurosci 2021;15:753915. [PMID: 34712115 DOI: 10.3389/fnins.2021.753915] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
20 Ilie OD, Paduraru E, Robea MA, Balmus IM, Jijie R, Nicoara M, Ciobica A, Nita IB, Dobrin R, Doroftei B. The Possible Role of Bifidobacterium longum BB536 and Lactobacillus rhamnosus HN001 on Locomotor Activity and Oxidative Stress in a Rotenone-Induced Zebrafish Model of Parkinson's Disease. Oxid Med Cell Longev 2021;2021:9629102. [PMID: 34691361 DOI: 10.1155/2021/9629102] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 Yan Y, Ren S, Duan Y, Lu C, Niu Y, Wang Z, Inglis B, Ji W, Zheng Y, Si W. Gut microbiota and metabolites of α-synuclein transgenic monkey models with early stage of Parkinson's disease. NPJ Biofilms Microbiomes 2021;7:69. [PMID: 34475403 DOI: 10.1038/s41522-021-00242-3] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
22 Zhao Z, Li F, Ning J, Peng R, Shang J, Liu H, Shang M, Bao XQ, Zhang D. Novel compound FLZ alleviates rotenone-induced PD mouse model by suppressing TLR4/MyD88/NF-κB pathway through microbiota-gut-brain axis. Acta Pharm Sin B 2021;11:2859-79. [PMID: 34589401 DOI: 10.1016/j.apsb.2021.03.020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
23 Socała K, Doboszewska U, Szopa A, Serefko A, Włodarczyk M, Zielińska A, Poleszak E, Fichna J, Wlaź P. The role of microbiota-gut-brain axis in neuropsychiatric and neurological disorders. Pharmacol Res 2021;172:105840. [PMID: 34450312 DOI: 10.1016/j.phrs.2021.105840] [Cited by in Crossref: 1] [Cited by in F6Publishing: 20] [Article Influence: 1.0] [Reference Citation Analysis]
24 Houser MC, Caudle WM, Chang J, Kannarkat GT, Yang Y, Kelly SD, Oliver D, Joers V, Shannon KM, Keshavarzian A, Tansey MG. Experimental colitis promotes sustained, sex-dependent, T-cell-associated neuroinflammation and parkinsonian neuropathology. Acta Neuropathol Commun 2021;9:139. [PMID: 34412704 DOI: 10.1186/s40478-021-01240-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
25 Han Y, Wang T, Li C, Wang Z, Zhao Y, He J, Fu L, Han B. Ginsenoside Rg3 exerts a neuroprotective effect in rotenone-induced Parkinson's disease mice via its anti-oxidative properties. Eur J Pharmacol 2021;909:174413. [PMID: 34391769 DOI: 10.1016/j.ejphar.2021.174413] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
26 Rosenberg HJ, Rao M. Enteric glia in homeostasis and disease: From fundamental biology to human pathology. iScience 2021;24:102863. [PMID: 34401661 DOI: 10.1016/j.isci.2021.102863] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
27 Chen Y, Xu J, Chen Y. Regulation of Neurotransmitters by the Gut Microbiota and Effects on Cognition in Neurological Disorders. Nutrients 2021;13:2099. [PMID: 34205336 DOI: 10.3390/nu13062099] [Cited by in F6Publishing: 37] [Reference Citation Analysis]
28 Fang P, Kazmi SA, Jameson KG, Hsiao EY. The Microbiome as a Modifier of Neurodegenerative Disease Risk. Cell Host Microbe 2020;28:201-22. [PMID: 32791113 DOI: 10.1016/j.chom.2020.06.008] [Cited by in Crossref: 11] [Cited by in F6Publishing: 43] [Article Influence: 11.0] [Reference Citation Analysis]
29 Innos J, Hickey MA. Using Rotenone to Model Parkinson's Disease in Mice: A Review of the Role of Pharmacokinetics. Chem Res Toxicol 2021;34:1223-39. [PMID: 33961406 DOI: 10.1021/acs.chemrestox.0c00522] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
30 Huang Y, Liao J, Liu X, Zhong Y, Cai X, Long L. Review: The Role of Intestinal Dysbiosis in Parkinson's Disease. Front Cell Infect Microbiol 2021;11:615075. [PMID: 33968794 DOI: 10.3389/fcimb.2021.615075] [Cited by in Crossref: 2] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
31 Ojeda J, Ávila A, Vidal PM. Gut Microbiota Interaction with the Central Nervous System throughout Life. J Clin Med 2021;10:1299. [PMID: 33801153 DOI: 10.3390/jcm10061299] [Cited by in Crossref: 3] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
32 Hou YF, Shan C, Zhuang SY, Zhuang QQ, Ghosh A, Zhu KC, Kong XK, Wang SM, Gong YL, Yang YY, Tao B, Sun LH, Zhao HY, Guo XZ, Wang WQ, Ning G, Gu YY, Li ST, Liu JM. Gut microbiota-derived propionate mediates the neuroprotective effect of osteocalcin in a mouse model of Parkinson's disease. Microbiome 2021;9:34. [PMID: 33517890 DOI: 10.1186/s40168-020-00988-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 27] [Article Influence: 6.0] [Reference Citation Analysis]
33 Dwyer Z, Chaiquin M, Landrigan J, Ayoub K, Shail P, Rocha J, Childers CL, Storey KB, Philpott DJ, Sun H, Hayley S. The impact of dextran sodium sulphate and probiotic pre-treatment in a murine model of Parkinson's disease. J Neuroinflammation 2021;18:20. [PMID: 33422110 DOI: 10.1186/s12974-020-02062-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
34 Kang Y, Kang X, Zhang H, Liu Q, Yang H, Fan W. Gut Microbiota and Parkinson's Disease: Implications for Faecal Microbiota Transplantation Therapy. ASN Neuro 2021;13:17590914211016217. [PMID: 34053243 DOI: 10.1177/17590914211016217] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
35 Benvenuti L, D'Antongiovanni V, Pellegrini C, Antonioli L, Bernardini N, Blandizzi C, Fornai M. Enteric Glia at the Crossroads between Intestinal Immune System and Epithelial Barrier: Implications for Parkinson Disease. Int J Mol Sci 2020;21:E9199. [PMID: 33276665 DOI: 10.3390/ijms21239199] [Cited by in Crossref: 2] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
36 Morais LH, Schreiber HL 4th, Mazmanian SK. The gut microbiota-brain axis in behaviour and brain disorders. Nat Rev Microbiol 2021;19:241-55. [PMID: 33093662 DOI: 10.1038/s41579-020-00460-0] [Cited by in Crossref: 55] [Cited by in F6Publishing: 244] [Article Influence: 27.5] [Reference Citation Analysis]
37 Zhang X, Yi N. Fast zero-inflated negative binomial mixed modeling approach for analyzing longitudinal metagenomics data. Bioinformatics 2020;36:2345-51. [PMID: 31904815 DOI: 10.1093/bioinformatics/btz973] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
38 Singh Y, Trautwein C, Dhariwal A, Salker MS, Alauddin M, Zizmare L, Pelzl L, Feger M, Admard J, Casadei N, Föller M, Pachauri V, Park DS, Mak TW, Frick JS, Wallwiener D, Brucker SY, Lang F, Riess O. DJ-1 (Park7) affects the gut microbiome, metabolites and the development of innate lymphoid cells (ILCs). Sci Rep 2020;10:16131. [PMID: 32999308 DOI: 10.1038/s41598-020-72903-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
39 Trabjerg MS, Mørkholt AS, Lichota J, Oklinski MKE, Andersen DC, Jønsson K, Mørk K, Skjønnemand MN, Kroese LJ, Pritchard CEJ, Huijbers IJ, Gazerani P, Corthals A, Nieland JDV. Dysregulation of metabolic pathways by carnitine palmitoyl-transferase 1 plays a key role in central nervous system disorders: experimental evidence based on animal models. Sci Rep 2020;10:15583. [PMID: 32973137 DOI: 10.1038/s41598-020-72638-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
40 Bhattarai Y, Kashyap PC. Parkinson's disease: Are gut microbes involved? Am J Physiol Gastrointest Liver Physiol 2020;319:G529-40. [PMID: 32877215 DOI: 10.1152/ajpgi.00058.2020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
41 Qian Y, Yang X, Xu S, Huang P, Li B, Du J, He Y, Su B, Xu L, Wang L, Huang R, Chen S, Xiao Q. Gut metagenomics-derived genes as potential biomarkers of Parkinson’s disease. Brain 2020;143:2474-89. [DOI: 10.1093/brain/awaa201] [Cited by in Crossref: 10] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
42 Farombi EO, Awogbindin IO, Olorunkalu PD, Ogbuewu E, Oyetunde BF, Agedah AE, Adeniyi PA. Kolaviron protects against nigrostriatal degeneration and gut oxidative damage in a stereotaxic rotenone model of Parkinson's disease. Psychopharmacology (Berl) 2020;237:3225-36. [PMID: 32651640 DOI: 10.1007/s00213-020-05605-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
43 Zhou ZL, Jia XB, Sun MF, Zhu YL, Qiao CM, Zhang BP, Zhao LP, Yang Q, Cui C, Chen X, Shen YQ. Neuroprotection of Fasting Mimicking Diet on MPTP-Induced Parkinson's Disease Mice via Gut Microbiota and Metabolites. Neurotherapeutics 2019;16:741-60. [PMID: 30815845 DOI: 10.1007/s13311-019-00719-2] [Cited by in Crossref: 37] [Cited by in F6Publishing: 62] [Article Influence: 18.5] [Reference Citation Analysis]
44 Harsanyiova J, Buday T, Kralova Trancikova A. Parkinson's Disease and the Gut: Future Perspectives for Early Diagnosis. Front Neurosci 2020;14:626. [PMID: 32625058 DOI: 10.3389/fnins.2020.00626] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
45 Vuotto C, Battistini L, Caltagirone C, Borsellino G. Gut Microbiota and Disorders of the Central Nervous System. Neuroscientist 2020;26:487-502. [PMID: 32441219 DOI: 10.1177/1073858420918826] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
46 Zhu X, Ji X, Shou Y, Huang Y, Hu Y, Wang H. Recent advances in understanding the mechanisms of PM2.5-mediated neurodegenerative diseases. Toxicol Lett 2020;329:31-7. [PMID: 32360789 DOI: 10.1016/j.toxlet.2020.04.017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
47 Mendonça IP, Duarte-Silva E, Chaves-Filho AJM, Andrade da Costa BLDS, Peixoto CA. Neurobiological findings underlying depressive behavior in Parkinson's disease: A review. Int Immunopharmacol 2020;83:106434. [PMID: 32224442 DOI: 10.1016/j.intimp.2020.106434] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
48 Shen L. Gut, oral and nasal microbiota and Parkinson's disease. Microb Cell Fact 2020;19:50. [PMID: 32103766 DOI: 10.1186/s12934-020-01313-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
49 Hu AL, Song S, Li Y, Xu SF, Zhang F, Li C, Liu J. Mercury sulfide-containing Hua-Feng-Dan and 70W (Rannasangpei) protect against LPS plus MPTP-induced neurotoxicity and disturbance of gut microbiota in mice. J Ethnopharmacol 2020;254:112674. [PMID: 32105745 DOI: 10.1016/j.jep.2020.112674] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
50 Chen C, Zhang B, Hu A, Li H, Liu J, Zhang F. Protective role of cinnabar and realgar in Hua-Feng-Dan against LPS plus rotenone-induced neurotoxicity and disturbance of gut microbiota in rats. Journal of Ethnopharmacology 2020;247:112299. [DOI: 10.1016/j.jep.2019.112299] [Cited by in Crossref: 6] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
51 Haikal C, Chen QQ, Li JY. Microbiome changes: an indicator of Parkinson's disease? Transl Neurodegener 2019;8:38. [PMID: 31890161 DOI: 10.1186/s40035-019-0175-7] [Cited by in Crossref: 27] [Cited by in F6Publishing: 36] [Article Influence: 9.0] [Reference Citation Analysis]
52 Xie W, Gao J, Jiang R, Liu X, Lai F, Tang Y, Xiao H, Jia Y, Bai Q. Twice subacute MPTP administrations induced time-dependent dopaminergic neurodegeneration and inflammation in midbrain and ileum, as well as gut microbiota disorders in PD mice. Neurotoxicology 2020;76:200-12. [PMID: 31790727 DOI: 10.1016/j.neuro.2019.11.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
53 Jin M, Li J, Liu F, Lyu N, Wang K, Wang L, Liang S, Tao H, Zhu B, Alkasir R. Analysis of the Gut Microflora in Patients With Parkinson's Disease. Front Neurosci 2019;13:1184. [PMID: 31824239 DOI: 10.3389/fnins.2019.01184] [Cited by in Crossref: 9] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
54 Bullich C, Keshavarzian A, Garssen J, Kraneveld A, Perez-Pardo P. Gut Vibes in Parkinson's Disease: The Microbiota-Gut-Brain Axis. Mov Disord Clin Pract 2019;6:639-51. [PMID: 31745471 DOI: 10.1002/mdc3.12840] [Cited by in Crossref: 20] [Cited by in F6Publishing: 31] [Article Influence: 6.7] [Reference Citation Analysis]
55 Ghaisas S, Langley MR, Palanisamy BN, Dutta S, Narayanaswamy K, Plummer PJ, Sarkar S, Ay M, Jin H, Anantharam V, Kanthasamy A, Kanthasamy AG. MitoPark transgenic mouse model recapitulates the gastrointestinal dysfunction and gut-microbiome changes of Parkinson's disease. Neurotoxicology 2019;75:186-99. [PMID: 31505196 DOI: 10.1016/j.neuro.2019.09.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
56 Dempsey JL, Little M, Cui JY. Gut microbiome: An intermediary to neurotoxicity. Neurotoxicology 2019;75:41-69. [PMID: 31454513 DOI: 10.1016/j.neuro.2019.08.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
57 Gazerani P. Probiotics for Parkinson's Disease. Int J Mol Sci 2019;20:E4121. [PMID: 31450864 DOI: 10.3390/ijms20174121] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 11.0] [Reference Citation Analysis]
58 Gorecki AM, Preskey L, Bakeberg MC, Kenna JE, Gildenhuys C, MacDougall G, Dunlop SA, Mastaglia FL, Akkari PA, Koengten F, Anderton RS. Altered Gut Microbiome in Parkinson's Disease and the Influence of Lipopolysaccharide in a Human α-Synuclein Over-Expressing Mouse Model. Front Neurosci 2019;13:839. [PMID: 31440136 DOI: 10.3389/fnins.2019.00839] [Cited by in Crossref: 48] [Cited by in F6Publishing: 65] [Article Influence: 16.0] [Reference Citation Analysis]
59 Riederer P, Berg D, Casadei N, Cheng F, Classen J, Dresel C, Jost W, Krüger R, Müller T, Reichmann H, Rieß O, Storch A, Strobel S, van Eimeren T, Völker HU, Winkler J, Winklhofer KF, Wüllner U, Zunke F, Monoranu CM. α-Synuclein in Parkinson's disease: causal or bystander? J Neural Transm (Vienna) 2019;126:815-40. [PMID: 31240402 DOI: 10.1007/s00702-019-02025-9] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 13.7] [Reference Citation Analysis]
60 Koh H, Li Y, Zhan X, Chen J, Zhao N. A Distance-Based Kernel Association Test Based on the Generalized Linear Mixed Model for Correlated Microbiome Studies. Front Genet 2019;10:458. [PMID: 31156711 DOI: 10.3389/fgene.2019.00458] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
61 Metzger JM, Emborg ME. Autonomic dysfunction in Parkinson disease and animal models. Clin Auton Res 2019;29:397-414. [PMID: 30604165 DOI: 10.1007/s10286-018-00584-7] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 6.3] [Reference Citation Analysis]
62 Radisavljevic N, Cirstea M, Brett Finlay B. Bottoms up: the role of gut microbiota in brain health. Environ Microbiol 2018. [PMID: 30556271 DOI: 10.1111/1462-2920.14506] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
63 Kujawska M, Jodynis-Liebert J. What is the Evidence That Parkinson's Disease is a Prion Disorder, Which Originates in the Gut? Int J Mol Sci 2018;19:E3573. [PMID: 30424585 DOI: 10.3390/ijms19113573] [Cited by in Crossref: 17] [Cited by in F6Publishing: 22] [Article Influence: 4.3] [Reference Citation Analysis]
64 Fang X. Microbial treatment: the potential application for Parkinson's disease. Neurol Sci 2019;40:51-8. [PMID: 30415447 DOI: 10.1007/s10072-018-3641-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
65 Perez-pardo P, Dodiya H, Engen P, Naqib A, Forsyth C, Green S, Garssen J, Keshavarzian A, Kraneveld A. Gut bacterial composition in a mouse model of Parkinson’s disease. Beneficial Microbes 2018;9:799-814. [DOI: 10.3920/bm2017.0202] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 9.0] [Reference Citation Analysis]
66 Pellegrini C, Antonioli L, Colucci R, Blandizzi C, Fornai M. Interplay among gut microbiota, intestinal mucosal barrier and enteric neuro-immune system: a common path to neurodegenerative diseases? Acta Neuropathol 2018;136:345-61. [PMID: 29797112 DOI: 10.1007/s00401-018-1856-5] [Cited by in Crossref: 99] [Cited by in F6Publishing: 98] [Article Influence: 24.8] [Reference Citation Analysis]
67 Lai F, Jiang R, Xie W, Liu X, Tang Y, Xiao H, Gao J, Jia Y, Bai Q. Intestinal Pathology and Gut Microbiota Alterations in a Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) Mouse Model of Parkinson's Disease. Neurochem Res 2018;43:1986-99. [PMID: 30171422 DOI: 10.1007/s11064-018-2620-x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 63] [Article Influence: 11.5] [Reference Citation Analysis]
68 Sun MF, Shen YQ. Dysbiosis of gut microbiota and microbial metabolites in Parkinson's Disease. Ageing Res Rev 2018;45:53-61. [PMID: 29705121 DOI: 10.1016/j.arr.2018.04.004] [Cited by in Crossref: 136] [Cited by in F6Publishing: 141] [Article Influence: 34.0] [Reference Citation Analysis]
69 Qian Y, Yang X, Xu S, Wu C, Song Y, Qin N, Chen SD, Xiao Q. Alteration of the fecal microbiota in Chinese patients with Parkinson's disease. Brain Behav Immun. 2018;70:194-202. [PMID: 29501802 DOI: 10.1016/j.bbi.2018.02.016] [Cited by in Crossref: 126] [Cited by in F6Publishing: 170] [Article Influence: 31.5] [Reference Citation Analysis]